Five things for pharma marketers to know: Thursday, December 3, 2015

Photo credit: Bill Brooks/Creative Commons

1. US healthcare spending rose by 5.3% in 2014—hitting $3 trillion. The share of GDP devoted to healthcare spending was 17.5%, up from 17.3% in 2013. Similarly, retail prescription drug spending grew by 12.2% in 2014. The accelerated rate of spending was attributed to the growth in private healthcare insurance and Medicaid spending. (Health Affairs)

2. Publicis announced a reorganization, effective January 2, that will create four groups within its agency network: Publicis Communications, Publicis Media, Publicis.Sapient and Publicis Healthcare. The network chose to reorganize its business units to un-silo them and place them in a better position to offer more integrated services to clients. (Ad Age)

3. New Jersey is weighing whether to punish drugmakers that redomicile abroad for tax benefits. If it ultimately chooses to do so, it would be the first state to adopt this kind of legislation. The proposed bill would end state contracts with and limit incentives to drugmakers that undergo these so-called tax inversions. (Bloomberg Business)

4. Medicare beneficiaries are doling out thousands of dollars in out-of-pocket costs for prescription drugs, even those individuals whose plans cover most treatments. An analysis by the Kaiser Family Foundation found that seniors taking cancer drug Revlimid could end up paying $11,538 of their own money in 2016, even though the drug is covered under their Medicare prescription drug plan. (NPR)

5. An FDA advisory committee voted 9-4 against recommending approval for antidepressant gepirone hydrochloride extended release, which has been denied regulatory clearance three times by the FDA. The drug is manufactured by Fabre Kramer Pharmaceuticals, the third company to own the drug's rights.  (MedPage Today)